hotspot -WSS

hotspot

author：Wikipedia 2025-09-29 21:26:10 - browse：75

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： A new initiative will help leaders fight the next pandemic

entertainment

leisure time

WSS

CMS got Medicare Advantage quality rating wrong, judge rules

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

Structure Therapeutics oral GLP

ASCO Takeaways: Winners, snoozers, and the art of cancer care

FDA approves Moderna’s RSV vaccine, its second licensed product

Senators tussle over abortion against the backdrop of a presidential campaign

entertainment

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

Affirmative action in medical school literally saved lives

Antibody drugs appear effective. Now can we make enough of them?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Data don't support strong claims for Covid

Cancer drug shortages should be causing more outrage

Eli Lilly’s Zepbound improved liver scarring in mid

In age of alternative facts, a scholarly course on calling out crap

Tornado touches down near Chicago's O'Hare airport amid extreme weather nationwide

BioMarin wins approval for gene therapy to treat hemophilia A

Structure Therapeutics oral GLP

explore

BD to buy Edwards patient monitoring unit for $4.2 billion

FDA approves Moderna’s RSV vaccine, its second licensed product

CMS got Medicare Advantage quality rating wrong, judge rules

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

STAT wants to know your pick for a great summer read or listen

Finland to offer bird flu vaccine to select groups of people, a possible global first

entertainment

leisure time

hotspot

focus